

## Market Round-up

V26 – 23<sup>rd</sup> November, 2018

### General Market News:

- Cardiff University has formed a drug discovery collaboration with **Takeda** to identify new approaches for treating **schizophrenia** and other psychiatric disorders.  
[LINK](#)
- The European Commission has given its blessing for the proposed £46-billion acquisition of **Shire** by **Takeda**, paving the way for the deal's completion.  
[LINK](#)
- **GSK** has retained its top position among a global list of pharmaceutical companies striving to make their medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.  
[LINK](#)
- The **NHS** has set up the first *Rare Disease Collaborative Network* for **refractory coeliac disease**  
[LINK](#)
- A late-stage study testing **MSD** and **Pfizer's** PD-L1 antibody **Bavencio** has failed to meet its primary endpoints in patients with certain forms of **ovarian cancer**.  
[LINK](#)
- **Boston Scientific** makes \$4.2B offer to buy **BTG** and build out its oncology, vascular franchises  
[LINK](#)
- **hmR International** acquires majority stake in **ActOne, S.A.**  
[LINK](#)

### NCPE Drug Updates

- No updates.

### Biologics / Biosimilars:

- **GSK** is seeking to expand the use of its biologic **Nucala** in the US to include children aged six to 11 years with severe **eosinophilic asthma**.  
[LINK](#)

### Drug Approvals/Filings:

- The European Commission has approved **Eli Lilly's Emgality** for **migraine**.  
[LINK](#)
- The US approves US OKs first treatment for **haemophagocytic lymphohistiocytosis**  
[LINK](#)

- Four medicines have taken a giant leap closer to approval having won the backing of the *European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)*.
  - **Janssen's Erleada** (apalutamide)
  - **Aeterna Zentaris' Macimorelin Aeterna Zentaris** (macimorelin)
  - **Recordati's generic Silodosin Recordati** (silodosin)
  - **Sanofi's Fexinidazole Winthrop** (fexinidazole)
- The FDA has approved **Pfizer's** drug **Daurismo** to treat a form of blood cancer in newly diagnosed patients as a combination therapy.

[LINK](#)

### **Further Reading:**

- Karen Aiach had no background in healthcare when her daughter received a diagnosis of a rare disease. She then founded **LYSOGENE** which is working to create the world's first treatment for **Sanfilippo Syndrome**.

[LINK](#)

- Key 8 predictions for Global Health Industry in 2019

[LINK](#)

- In a recently published study by Access to Medicine Foundation, 63% of priority R&D projects are being conducted by five companies: **GSK, Johnson & Johnson, MSD, Novartis** and **Sanofi**

[LINK](#)

-----